Media inquiries

Stephanie Simon
(617) 581-9333

A New Approach to Treating Multiple Sclerosis

Press releases

September 19, 2017 – Disarm Therapeutics Unveils Breakthrough Approach to Treat Patients with Neurological Diseases by Preventing Axonal Degeneration
Announces $30 Million Series A Financing Led by Atlas Venture, with Co-Investors Lightstone Ventures and AbbVie Ventures

Publications

SARM1: the Central Driver of Axonal Degeneration

SARM1 Deletion Protects Axons in a Model of Inflammatory Demyelination
Krauss R, Hughes R, Bosanac T, Devraj R, Engber T
Presented at the European Committee for Treatment and Research in Multiple Sclerosis. 2019 September 13

Vincristine and bortezomib use distinct upstream mechanisms to activate a common SARM1-dependent axon degeneration program
Geisler S, Doan R, Cheng G, Cetinkaya-Fisgin A, Huang S, Höke A, Milbrandt J, DiAntonio A
JCI Insight. 2019;4(17):e129920

SARM1 Loss of Function Prevents Degeneration of Peripheral and Central Axons
Krauss R, Hughes R, Bosanac T, Devraj R, Engber T
Presented at the Annual Meeting of the American Academy of Neurology. 2019 May 4

Axon degeneration: mechanistic insights lead to therapeutic opportunities for the prevention and treatment of peripheral neuropathy
DiAntonio A
Pain. 2019 May;160 Suppl 1:S17-S22.

cADPR and NF-L are SARM1-Dependent Biomarkers of Axonal Structure and Function that Enable Therapeutic Discovery and Clinical Translation
Krauss R, Engber T, Hughes R, Bosanac T, Devraj R
Presented at the Molecular Mechanisms of Axon Degeneration Meeting. 2019 March 11

SARM1 Deletion Prevents Degeneration of Peripheral and Central Axons
Krauss R, Engber T, Devraj R, Bosanac T, Hughes R
Presented at the Neuroscience 2018 conference. 2018 November 3

Development of SARM1 Inhibitors to Treat Peripheral Neuropathies
Hughes R, Devraj R, Engber T, Bosanac T, Krauss R
Presented at the 2018 Peripheral Nerve Society Annual Meeting. 2018 July 23

Sarm1/Myd88-5 Regulates Neuronal Intrinsic Immune Response to Traumatic Axonal Injuries
Wang Q, Zhang S, Liu T, Wang H, Liu K, Wang Q, Zeng W
Cell Rep. 2018 Apr 17;23(3):716-724.

Sarm1 Deletion, but Not WldS, Confers Lifelong Rescue in a Mouse Model of Severe Axonopathy
Gilley J, Ribchester R, Coleman M
Cell Rep. 2017 Oct 3;21(1):10-16

Deletion of Sarm1 gene is neuroprotective in two models of peripheral neuropathy
Turkiew E, Falconer D, Reed N, Höke A
J Peripher Nerv Syst. 2017 Sep;22(3)

The SARM1 Toll/Interleukin-1 Receptor Domain Possesses Intrinsic NAD+ Cleavage Activity that Promotes Pathological Axonal Degeneration
Essuman K, Summers DW, Sasaki Y, Mao X, DiAntonio A, Milbrandt J
Neuron. 2017 Mar 22;93(6):1334-1343

Prevention of vincristine-induced peripheral neuropathy by genetic deletion of SARM1 in mice
Geisler S, Doan RA, Strickland A, Huang X, Milbrandt J, DiAntonio A
Brain. 2016 Dec;139(Pt 12):3092-3108.

SARM1-specific motifs in the TIR domain enable NAD+ loss and regulate injury-induced SARM1 activation
Summers DW, Gibson DA, DiAntonio A, Milbrandt J
Proc Natl Acad Sci U S A. 2016 Oct 11;113(41):E6271-E6280

Axon Self-Destruction: New Links among SARM1, MAPKs, and NAD+ Metabolism
Gerdts J, Summers DW, Milbrandt J, DiAntonio A
Neuron. 2016 Feb 3;89(3):449-60

SARM1 activation triggers axon degeneration locally via NAD⁺ destruction
Gerdts J, Brace EJ, Sasaki Y, DiAntonio A, Milbrandt J
Science. 2015 Apr 24;348(6233):453-7

Mitochondrial dysfunction induces Sarm1-dependent cell death in sensory neurons
Summers DW, DiAntonio A, Milbrandt J
J Neurosci. 2014 Jul 9;34(28):9338-50

Sarm1-mediated axon degeneration requires both SAM and TIR interactions
Gerdts J, Summers DW, Sasaki Y, DiAntonio A, Milbrandt J
J Neurosci. 2013 Aug 14;33(33):13569-80

Measuring Axonal Degeneration

Neurofilaments as biomarkers in neurological disorders
Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer M, Barro C, Kappos L, Comabella M, Fazekas F, Petzold A, Blennow K, Zetterberg H, Kuhle J
Nature Reviews Neurology (2018)

Neurofilament light chain as disease biomarker in a rodent model of chemotherapy induced peripheral neuropathy
Meregalli C, Fumagalli G, Alberti P, Canta A, Carozzi VI, Chiorazzi A, Monza L, Pozzi E, Sandelius Å, Blennow K, Zetterberg H, Marmiroli P, Cavaletti G
Experimental Neurology, Volume 307, September 2018, Pages 129-132

Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis
Barro C, Benkert P, Disanto G, Tsagkas C, Amann M, Naegelin Y, Leppert D, Gobbi C, Granziera C, Yaldizli Ö, Michalak Z, Wuerfel J, Kappos L, Parmar K, Kuhle J
Brain, Volume 141, Issue 8, 1 August 2018, Pages 2382–2391

Serum Neurofilament Light: A Biomarker of Neuronal Damage in Multiple Sclerosis
Disanto G, Barro C, Benkert P, Naegelin Y, Schädelin S, Giardiello A, Zecca C, Blennow K, Zetterberg H Leppert D, Kappos L, Gobbi, C, Kuhle J, and the Swiss Multiple Sclerosis Cohort Study Group
ANN NEUROL 2017;81:857–870

Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis
Lu CH, Macdonald-Wallis C, Gray E, Pearce N, Petzold A, Norgren N, Giovannoni G, Fratta P, Sidle K, Fish M, Orrell R, Howard R, Talbot K, Greensmith L, Kuhle J, Turner MR, Malaspina A
Neurology. 2015 Jun 2; 84(22): 2247–225